A short peptide from Vladimir Khavinson’s bioregulator programme directed at ovarian tissue, the female counterpart to Testagen within the family.

Why are ovaries fundamentally different from testes?

Because they do not manufacture. Every egg is present before birth and the number only decreases thereafter, whereas the testes produce continuously for decades. That makes ovarian research a question of maintaining a fixed supply rather than supporting ongoing production.

How strong is the evidence?

Limited — small, preclinical and largely from the originating institute, with no regulatory approval anywhere.

Why is the ovary unusual among organs?

Because it does not manufacture. Every egg is present before birth and the number only falls from that point on, unlike the testes which produce new cells continuously for decades. The ovary distributes from a fixed supply rather than replenishing one.

Research Library›Bioregulators & Neuropeptides›Ovagen

Ovarian Bioregulator

Ovagen: The Peptide for an Organ Working From a Fixed Supply

Q: Why does that make ovarian research different?

Because the question becomes preservation rather than production. The cells are not fresh — they are the same cells held in suspended animation for decades — so age affects quality as well as quantity, and there is no renewal process to support.

A short peptide aimed at ovarian tissue — an organ that, uniquely, is issued its entire lifetime stock before birth and can never make more.

5 min read·4 studies cited·Updated July 2026

Evidence level

Preclinical only — animal and cell studies

What this level means

Quick Reference

Type	Short peptide
Target tissue	Ovaries
Studied for	Ovarian tissue function
Generation	Synthetic

What Is Ovagen?

Ovagen is a short peptide from the Khavinson family directed at ovarian tissue, and the female counterpart to Testagen within the programme.

A supply that only ever goes down, in plain language: here the contrast with the male side is stark. Testes manufacture continuously — a production line running for decades. Ovaries do not manufacture at all. Every egg a woman will ever have is present before she is born, and from that moment the number only falls. It is the difference between a factory and a pantry stocked once, at the beginning, with no possibility of restocking. That single biological fact shapes almost all ovarian research, because the question can never be how to make more — only how well what remains is maintained.

What the Research Examines

Published work examines ovarian tissue function and related markers in animal models, generally in the context of age-related change.

As with the rest of the synthesised family, the literature is small, preclinical and originates chiefly from the developing institute. There is no regulatory approval in any jurisdiction.

The Only Stock You Will Ever Get

The ovary is unlike almost every other organ in one decisive respect: it does not manufacture. It distributes from a supply issued before birth and never added to.

The contrast with the male side is stark. Testes are a production line, making new cells continuously for decades. Ovaries are a pantry, stocked once, at the beginning, and drawn down from that moment on. Every egg a woman will ever have was present before she was born, and the number only ever falls.

That single structural fact explains a great deal. It explains why the reproductive span has a defined end while the male equivalent does not. It explains why age affects egg quality as well as quantity — these are not fresh cells, they are the same cells, held in suspended animation for decades.

Think of a wine cellar rather than a brewery. A brewery can always make more, and what it makes is new. A cellar has exactly what was laid down, and every bottle is as old as the day it went in. Maintenance in a cellar means preserving what is already there — there is no other option.

Which is why research interest in ovarian tissue centres on preservation rather than production. It is one of the few tissues where the question is genuinely about protecting an existing stock rather than supporting renewal.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed